Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Ordinary Shares, par value US$0.0001 per share
-
Shares outstanding
-
37.4M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
150K
-
Shares change
-
-130K
-
Total reported value, excl. options
-
$9.91M
-
Value change
-
-$8.04M
-
Number of buys
-
12
-
Number of sells
-
-14
-
Price
-
$66.22
Significant Holders of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE) as of Q1 2025
27 filings reported holding BLTE - BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share as of Q1 2025.
BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 150K shares
of 37.4M outstanding shares and own 0.4% of the company stock.
Largest 10 shareholders include Alyeska Investment Group, L.P. (83.6K shares), STATE STREET CORP (20.1K shares), GEODE CAPITAL MANAGEMENT, LLC (12.8K shares), JPMORGAN CHASE & CO (8.16K shares), CITADEL ADVISORS LLC (5.69K shares), BANK OF AMERICA CORP /DE/ (5.22K shares), HRT FINANCIAL LP (4.12K shares), AMERIPRISE FINANCIAL INC (3.08K shares), Virtus Investment Advisers, LLC (2.59K shares), and GAMMA Investing LLC (1.85K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.